“Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial” (2021) SKIN The Journal of Cutaneous Medicine, 5(6), p. s52. doi:10.25251/skin.5.supp.52.